论文部分内容阅读
根据一项涵盖17个国家(含中国)、纳入9901例T2DM患者的国际糖尿病治疗实践研究(IDMPS)结果显示,HbA1c未达标(≥7%)者高达63.6%,这与临床医生对胰岛素治疗及血糖控制目标上存在认识误区不无关系。大量研究结果证实,基础胰岛素治疗是T2DM治疗中极具潜力的治疗手段,它首先通过有效控制FPG进而达到改善全天血糖谱、降低DM并发症风险,并保护胰岛β细胞功能的目的。本文就近年来这一领域的一些观念和循证依据对DM治疗中FPG的意义加以探讨。
According to an International Diabetes Management Practice Study (IDMPS) study involving 9901 T2DM patients in 17 countries (including China), HbA1c was as high as 63.6% of patients who did not meet the criteria (≥7%), which is closely related to clinicians’ Blood sugar control objectives exist misunderstandings are not unrelated. Numerous studies have confirmed that basal insulin therapy is a potential therapeutic approach in the treatment of T2DM. It first achieves the goal of improving blood glucose profile, reducing the risk of DM complications and protecting the function of pancreatic β-cells by effectively controlling FPG. In this paper, some concepts and evidence-based evidence in this area in recent years to explore the significance of DM in the treatment of FPG.